Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study

被引：0
|
作者：
Myong Cheol Lim
Young-Joo Won
Jiwon Lim
Tahereh Salehi
Chong Woo Yoo
Robert E. Bristow
机构：
[1] University of California,Division of Gynecologic Oncology, Obstetrics and Gynecology, Irvine Medical Center
[2] Center for Uterine Cancer and Center for Clinical Trials,Department of Cancer Control & Population Health
[3] Hospital,Cancer Registration and Statistics Branch
[4] National Cancer Center,undefined
[5] Cancer Healthcare Research Branch,undefined
[6] Research Institute,undefined
[7] National Cancer Center,undefined
[8] Graduate School of Cancer Science and Policy,undefined
[9] National Cancer Center,undefined
[10] National Cancer Control Institute,undefined
[11] National Cancer Center,undefined
来源：
BMC Cancer | / 18卷
关键词：
Second primary; Ovarian cancer; Primary peritoneal cancer; Fallopian tubal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study
    Lim, Myong Cheol
    Won, Young-Joo
    Lim, Jiwon
    Salehi, Tahereh
    Yoo, Chong Woo
    Bristow, Robert E.
    BMC CANCER, 2018, 18
  • [2] SECOND PRIMARY CANCER AFTER PRIMARY PERITONEAL, EPITHELIAL OVARIAN, FALLOPIAN TUBAL CANCER
    Lim, M. C.
    Lim, J.
    Salehi, T.
    Young-Joo, L.
    Yoo, C. W.
    Bristow, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 754 - 754
  • [3] Second Primary Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers after Breast Cancer Diagnosis: Korea Central Cancer Registry
    Ha, Hyeong In
    Lee, Eun-Gyeong
    Lim, Jiwon
    Jung, So-Youn
    Chang, Yoon Jung
    Won, Young-Joo
    Lim, Myong Cheol
    CANCER RESEARCH AND TREATMENT, 2021, 53 (02): : 541 - 548
  • [4] Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer
    Webber, Kate
    Friedlander, Michael
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 41 : 126 - 138
  • [5] Efficacy of second line chemotherapeutic regimens in persistent or recurrent epithelial ovarian cancer including fallopian tube cancer and primary peritoneal cancer: A multicenter retrospective study
    Lee, H. P.
    Kim, Y. B.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 235 - 236
  • [6] Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
    Zagouri, Flora
    Sergentanis, Theodoros N.
    Chrysikos, Dimosthenis
    Dimopoulos, Meletios-Athanassios
    Bamias, Aristotle
    ONCOTARGETS AND THERAPY, 2015, 8 : 2187 - 2198
  • [7] Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Kerliu, Lloreta
    Myruski, Samantha
    Bhatti, Afeefa
    Soni, Priyal
    Petrosius, Paulius
    Pervanas, Helen C.
    Horton, Evan R.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (10) : 1010 - 1015
  • [8] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Sabbatini, Paul
    Dupont, Jakob
    Aghajanian, Carol
    Derosa, Felicia
    Poynor, Elizabeth
    Anderson, Sybil
    Hensley, Martee
    Livingston, Phillip
    Lasonos, Alexia
    Spriggs, David
    McGuire, William
    Reinartz, Silke
    Schneider, Sally
    Grande, Cathy
    Lele, Shashikant
    Rodabaugh, Kerry
    Kepner, James
    Ferrone, Soldano
    Odunsi, Kunle
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5503 - 5510
  • [9] Examining the impact of age on chemotherapy completion in epithelial ovarian, fallopian tube and primary peritoneal cancer: a retrospective cohort study in Thailand
    Assavapokee, Nicha
    Santibenchakul, Somsook
    Ratree, Sasivimon
    Lertkhachonsuk, Ruangsak
    Phoolcharoen, Natacha
    BMJ OPEN, 2024, 14 (07): : 1 - 11
  • [10] EFFECTIVENESS OF ORAL ETOPOSIDE IN RECURRENT OR REFRACTORY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CANCER AND FALLOPIAN TUBE CANCER
    Kongsawatvorakul, C.
    Charakorn, C.
    Chittithaworn, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 742 - 742
12345